Dr. Carmen Kreft-Jais, pharmacovigilance manager of the French Agency for Safety of Health Products (AFSSAPS), relativize the importance of narcolepsy-related vaccine against influenza A.
Why suggest a possible link between vaccination against influenza A and narcolepsy while the incidence of this neurological disorder has yet nothing to be alarmed?
You're right, with six cases to six million people vaccinated in France, the incidence rate is not abnormal. However, we must refine, see if new cases occur and make comparisons with previous years. There is a signal rather unusual: generally new cases of narcolepsy are not communicated to us. Unlike what happened in Sweden last week where the occurrence of these cases has generated huge media interest. The European Medicines Agency (EMA) announced Friday 27August having opened at the request of the European Commission, an investigation into the vaccine Pandemrix against H1N1, suspected of having caused the crises of narcolepsy in Finland and Sweden.
Why do we do we talk as Sweden, Finland and France? Are there figures for other countries?
Sweden and Finland are countries where vaccination coverage is particularly high. They are probably more attentive to potential side effects of the vaccine. In France, pharmacovigilance plays a very important role. Regarding the number of cases or other affected countries, we do not have additional statistics, we have no exact figure. We expect the scientific evaluation of the European Medical Agency (EMA).
In that case, why risk creating a new psychosis in people and not wait for the results of the EMA?
The problem is unfortunately complicated: if we do not communicate, we are taxed desire to conceal information. A Conversely, by making this public concern, we are rebuked for being too alarmist. We preferred to play the card of transparency.
By Kevin The Louargant in the Express
0 comments:
Post a Comment